AI assistant
DEXCOM INC — Director's Dealing 2020
Mar 11, 2020
30198_dirs_2020-03-10_be8a5dae-3551-4e69-9230-8ba722fca772.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2020-03-08
Reporting Person: Blackford Quentin S. (Chief Operating Officer & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-08 | Common Stock | A | 12727 | $0.001 | Acquired | 82655 | Direct |
| 2020-03-09 | Common Stock | S | 891 | $261.0 | Disposed | 81764 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2: Included in this number are 69,029 unvested restricted stock units, 12,727 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 12,288 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 31,180 of which were granted on September 7, 2017 and shall vest through September 7, 2021.
F3: On December 9, 2019, Mr. Blackford adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Blackford. The shares set forth above were sold pursuant to the 10b5-1 Plan.